- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05498428
Um estudo de amivantamab em participantes com tumores sólidos avançados ou metastáticos, incluindo câncer de pulmão de células não pequenas mutante do receptor do fator de crescimento epidérmico (EGFR) (PALOMA-2)
Um estudo de coorte paralelo, aberto, de fase 2, de amivantamab subcutâneo em regimes múltiplos em pacientes com tumores sólidos avançados ou metastáticos, incluindo câncer de pulmão de células não pequenas com mutação de EGFR
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Study Contact
- Número de telefone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Locais de estudo
-
-
-
Berlin, Alemanha, 13125
- Concluído
- Evangelische Lungenklinik Berlin
-
Cologne, Alemanha, 50937
- Recrutamento
- Universitaetsklinikum Koeln
-
Grosshandorf, Alemanha, 22927
- Recrutamento
- LungenClinic Grosshansdorf GmbH
-
Immenhausen, Alemanha, 34376
- Recrutamento
- Lungenfachklinik Immenhausen
-
Würzburg, Alemanha, 97074
- Recrutamento
- Klinikum Würzburg Mitte gGmbH Standort Missioklinik
-
-
-
-
-
Barretos, Brasil, 14784-400
- Recrutamento
- Fundacao Pio XII
-
Belo Horizonte, Brasil, 30130 090
- Recrutamento
- PERSONAL Oncologia de Precisao e Personalizada
-
Londrina, Brasil, 86015 520
- Recrutamento
- Hospital do Cancer de Londrina
-
Porto Alegre, Brasil, 90035-001
- Recrutamento
- Hospital Moinhos de Vento
-
Rio de Janeiro, Brasil, 22281 100
- Recrutamento
- IDOR - Regional Rio de Janeiro
-
Salvador, Brasil, 41253-190
- Recrutamento
- IDOR - Regional Bahia
-
São Paulo, Brasil, 01509 900
- Recrutamento
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasil, 01327 001
- Recrutamento
- Hospital Alemao Oswaldo Cruz
-
São Paulo, Brasil, 01409-001
- Concluído
- Impar Servicos Hospitalares SA Hospital Nove de Julho
-
-
-
-
-
Baoding, China, 071051
- Concluído
- Affiliated Hospital of Hebei University
-
Changchun, China, 130000
- Recrutamento
- Jilin cancer hospital
-
Chengdu, China, 610041
- Recrutamento
- Sichuan Cancer Hospital
-
Chengdu, China, 610047
- Recrutamento
- West China Hospital Sichuan University
-
Chongqing, China, 400038
- Recrutamento
- The First Affiliated Hospital of PLA Army Medical University
-
Guangzhou, China, 510060
- Recrutamento
- The First Affiliated Hospital Sun Yat sen University
-
Hangzhou, China, 310003
- Recrutamento
- The First Affiliated Hospital Zhejiang University College of Medicine
-
Hangzhou, China, 310016
- Recrutamento
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Harbin, China, 150000
- Recrutamento
- Harbin medical university cancer hospital
-
Huizhou, China, 516001
- Recrutamento
- Huizhou Municipal Central Hospital
-
Liuzhou, China, 545006
- Concluído
- Liuzhou people's Hospital
-
Shanghai, China, 200032
- Recrutamento
- Fudan University Shanghai Cancer Center
-
Tianjin, China, 300052
- Recrutamento
- Tianjin Medical University General Hospital
-
Wenzhou, China, 325000
- Recrutamento
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, China, 430022
- Recrutamento
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Wuxi, China, 214122
- Concluído
- Hospital of Jiangnan University
-
Xi'an, China, 710061
- Recrutamento
- The First Affiliated Hospital of Xian Jiaotong University
-
Yantai, China, 264000
- Concluído
- Yantai Yuhuangding Hospital
-
-
-
-
-
Goyang-si, Coréia do Sul, 10408
- Recrutamento
- National Cancer Center
-
Seongnam-si, Coréia do Sul, 13620
- Recrutamento
- Seoul National University Bundang Hospital
-
Seoul, Coréia do Sul, 03080
- Recrutamento
- Seoul National University Hospital
-
Seoul, Coréia do Sul, 03722
- Recrutamento
- Severance Hospital Yonsei University Health System
-
Seoul, Coréia do Sul, 05505
- Concluído
- Asan Medical Center
-
-
-
-
-
A Coruña, Espanha, 15006
- Recrutamento
- Hosp Univ A Coruna
-
Alicante, Espanha, 03010
- Recrutamento
- General University Hospital of Alicantet
-
Barcelona, Espanha, 08025
- Recrutamento
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Espanha, 08003
- Recrutamento
- Hosp. Del Mar
-
Barcelona, Espanha, 8908
- Recrutamento
- Inst. Cat. Doncologia-H Duran I Reynals
-
Barcelona, Espanha, 08035
- Recrutamento
- Hosp Univ Vall D Hebron
-
Madrid, Espanha, 28034
- Recrutamento
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Espanha, 28041
- Recrutamento
- Hosp. Univ. 12 de Octubre
-
Madrid, Espanha, 28046
- Recrutamento
- Hosp. Univ. La Paz
-
Madrid, Espanha, 28007
- Recrutamento
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga, Espanha, 29010
- Recrutamento
- Hosp Regional Univ de Malaga
-
Seville, Espanha, 41009
- Recrutamento
- Hosp. Virgen Macarena
-
Valencia, Espanha, 46010
- Recrutamento
- Hosp. Clinico Univ. de Valencia
-
Valencia, Espanha, 46014
- Recrutamento
- Hosp. Gral. Univ. Valencia
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92093
- Recrutamento
- University of California at San Diego
-
Orange, California, Estados Unidos, 92868
- Recrutamento
- University of California Irvine
-
Stanford, California, Estados Unidos, 94305
- Recrutamento
- Stanford Cancer Institute
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20016
- Recrutamento
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33486
- Concluído
- Baptist Lynn Cancer Institute
-
Miami Beach, Florida, Estados Unidos, 33140
- Recrutamento
- Mount Sinai Medical Center
-
Orlando, Florida, Estados Unidos, 32804
- Recrutamento
- AdventHealth
-
Tampa, Florida, Estados Unidos, 33612
- Concluído
- H. Lee Moffitt Cancer & Research Institute
-
-
Kansas
-
Westwood, Kansas, Estados Unidos, 66205
- Recrutamento
- University of Kansas Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Recrutamento
- Sidney Kimmel Cancer Center - Bayview Campus
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02118
- Recrutamento
- Boston Medical Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University School Of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Recrutamento
- Hackensack University Medical Center
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Recrutamento
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
East Syracuse, New York, Estados Unidos, 13057
- Concluído
- Hematology-Oncology Associates of CNY
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Concluído
- Novant Health 1
-
Winston-Salem, North Carolina, Estados Unidos, 27106
- Concluído
- Novant Health
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Concluído
- Cleveland Clinic
-
Cleveland, Ohio, Estados Unidos, 44111
- Concluído
- Cleveland Clinic 1
-
Mayfield Heights, Ohio, Estados Unidos, 44124
- Concluído
- Cleveland Clinic 2
-
Warrensville Heights, Ohio, Estados Unidos, 44122
- Concluído
- Cleveland Clinic 3
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Concluído
- The Huntsman Cancer Institute
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Recrutamento
- Virginia Cancer Specialists
-
-
Washington
-
Everett, Washington, Estados Unidos, 98201
- Concluído
- Providence Regional Cancer Partnership
-
Seattle, Washington, Estados Unidos, 98104
- Recrutamento
- Swedish Cancer Institute
-
Seattle, Washington, Estados Unidos, 98101
- Concluído
- Virginia Mason Medical Center
-
-
-
-
-
Caen, França, 14076
- Recrutamento
- Centre Francois Baclesse
-
Dijon, França, 21079
- Concluído
- Centre Georges-François Leclerc
-
Nîmes, França, 30029
- Recrutamento
- Institut de Cancérologie du Gard
-
Paris, França, 75248
- Recrutamento
- Institut Curie
-
Saint-Herblain, França, 44805
- Recrutamento
- Institut de cancerologie de l'ouest
-
Villejuif, França, 94800
- Recrutamento
- Gustave Roussy
-
-
-
-
-
Haifa, Israel, 3109601
- Recrutamento
- Rambam Medical Center
-
Jerusalem, Israel, 9103102
- Recrutamento
- Shaare Zedek Medical Center
-
Kfar Saba, Israel, 44281
- Concluído
- Meir Medical Center
-
Petah Tikva, Israel, 4941492
- Recrutamento
- Rabin Medical Center
-
Ramat Gan, Israel, 52621
- Recrutamento
- Sheba Medical Center
-
-
-
-
-
Genova, Itália, 16132
- Recrutamento
- Policlinico Hospital San Martino- IRCCS for Oncology
-
Milan, Itália, 20132
- Recrutamento
- Ospedale San Raffaele
-
Milan, Itália, 20162
- Recrutamento
- ASST Grande Ospedale Metropolitano Niguarda
-
Monza, Itália, 20090
- Recrutamento
- Azienda Ospedaliera San Gerardo
-
Naples, Itália, 80131
- Recrutamento
- Azienda Ospedaliera Specialistica dei Colli
-
-
-
-
-
Himeji, Japão, 670-8520
- Ativo, não recrutando
- National Hospital Organization Himeji Medical Center
-
Matsusaka, Japão, 515 8544
- Ativo, não recrutando
- Saiseikai Matsusaka Municipal Hospital
-
Niigata, Japão, 951-8566
- Ativo, não recrutando
- Niigata Cancer Center Hospital
-
Shizuoka, Japão, 411 8777
- Ativo, não recrutando
- Shizuoka Cancer Center
-
Tokyo, Japão, 135 8550
- Ativo, não recrutando
- The Cancer Institute Hospital of JFCR
-
Wakayama, Japão, 641 8510
- Ativo, não recrutando
- Wakayama Medical University Hospital
-
-
-
-
-
Kuala Lumpur, Malásia, 59100
- Recrutamento
- University Malaya Medical Centre
-
Kuantan, Malásia, 25100
- Recrutamento
- Hospital Tengku Ampuan Afzan
-
Kuching, Malásia, 93586
- Recrutamento
- Hospital Umum Sarawak
-
Petaling Jaya, Malásia, 46050
- Recrutamento
- Beacon Hospital Sdn Bhd
-
-
-
-
-
Cheltenham, Reino Unido, GL53 7AN
- Concluído
- Cheltenham General Hospital
-
Devon, Reino Unido, TQ2 7AA
- Recrutamento
- Torbay Hospital-Devon
-
Edinburgh, Reino Unido, EH4 2XU
- Recrutamento
- Edinburgh Cancer Centre Western General
-
Leicester, Reino Unido, LE1 5WW
- Recrutamento
- Leicester Royal Infirmary
-
London, Reino Unido, NW1 2PG
- Recrutamento
- University College London Hospitals
-
Nottingham, Reino Unido, NG5 1PB
- Recrutamento
- Nottingham City Hospital
-
Portsmouth, Reino Unido, PO6 3LY
- Recrutamento
- Queen Alexandra Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC) that is not amenable to curative therapy including surgical resection or chemoradiation. Additional Cohort specific disease requirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factor receptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation; Cohort 2: EGFR Exon 20ins mutation. Cohorts 1,5,and6: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohort 2: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohorts 3and3b: Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Cohort 4: Participants need to currently be on an amivantamab IV Q2W regimen (1,050 mg or 1,400 mg depending on weight) for at least 8 weeks, as part of standard of care, an expanded access program, or as a rollover from a long-term extension, without any amivantamab dose reduction. Cohort 7: Participants must have progressed on or after the combination of amivantamab and lazertinib as the most recent line of treatment. The combination of amivantamab and lazertinib must have been administered as the first-line treatment for locally advanced or metastatic disease. Cohort 2, 3, 3b, and 7 only: Squamous NSCLC are excluded. EGFR mutation must have been identified as determined by Food and Drug Administration (FDA) approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US). A copy of the initial test report documenting the EGFR mutation must be included in the participant records and a deidentified copy must also be submitted to the sponsor
- All cohorts except Cohort 4: Participants must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. If the only target lesion has been previously irradiated, it must show signs of disease progression since radiation was completed If only 1 non-irradiated measurable lesion exists, which undergoes a biopsy and is acceptable as a target lesion, the baseline tumor assessment scans should be performed at least 14 days after the biopsy
- May have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Have adequate organ (renal, hepatic, hematological, coagulation and cardiac) functions
- Participant must have eastern cooperative oncology group (ECOG) status of 0 or 1
- Cohort 6: Must be eligible for, and agree to comply with, the use of prophylactic anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months of study treatment
- A participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 6 months after receiving the last dose of study treatment. Participants with child bearing potential should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility
Exclusion Criteria:
- Participant has a medical history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis
- Participant has a history of hypersensitivity to any excipients of the investigational products to be used in their enrollment cohort
- Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines against Coronavirus disease 19 (COVID-19) are not exclusionary
- For all cohorts (with regimens potentially including lazertinib): Participant is currently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5) inducers and is unable to stop use for an appropriate washout period prior to Cycle 1 Day 1
- Other clinically active liver disease of infectious origin
- Participant has a history of clinically significant cardiovascular disease including, but not limited to: a) All cohorts: diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to the first dose of study treatment(s), or any of the following within 6 months prior to the first dose of study treatment(s): myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary; b) All cohorts (with regimens potentially including lazertinib): Participant has a significant genetic predisposition to venous thromboembolic events (VTE; such as Factor V Leiden); c) All cohorts (with regimens potentially including lazertinib): Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines; d) prolonged corrected QT interval by Fridericia (QTcF) interval greater than (>) 480 milliseconds (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease (example, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate); e) uncontrolled (persistent) hypertension: systolic blood pressure >160 millimeter(s) of mercury (mmHg); diastolic blood pressure >100 mmHg; f) Congestive heart failure defined as NYHA class III-IV or hospitalization for congestive heart failure (CHF) (any New York Heart Association [NYHA] class) within 6 months of treatment initiation at Cycle 1/day 1 (C1D1); g) pericarditis/clinically significant pericardial effusion; h) myocarditis; i) baseline left ventricular ejection fraction (LVEF) below the institution's lower limit of normal at screening, as assessed by echocardiogram or multigated acquisition (MUGA) scan
- Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have received definitive radiation or surgical treatment for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at least 2 weeks before Screening are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (less than or equal to [<=] 10 milligrams per day [mg/day] prednisone or equivalent) for at least 2 weeks prior to treatment allocation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q2W) + Lazertinib
Participants with treatment-naive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) exon 19 deletion (exon19del) or exon 21 leucine 858 to arginine substitution (exon 21 L858R) mutation, will receive amivantamab SC-CF injection, 1600 milligrams (mg) or 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily. Eligible participants will be given an option to enter long-term extension (LTE) phase and may continue to receive access to study treatment(s) within the study by transferring to the Drug Access (DA)-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Lazertinib will be administered as an oral tablet.
Outros nomes:
|
|
Experimental: Cohort 2(Exon20 NSCLC,1L, Previously Untreated): Amivantamab (Q3W) + Chemotherapy
Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR exon20ins mutation will receive Amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle, starting with Cycle 2 along with pemetrexed 500 milligrams per meter square (mg/m^2) as intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and IV infusion carboplatin area under the concentration-time curve 5 milligrams per milliliters (mg/mL) per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
|
Experimental: Cohort 3(Exon19del/Exon21 L858R NSCLC,2L,Post Osimertinib):Amivantamab(Q3W)+Lazertinib+Chemotherapy
Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Lazertinib 240 mg orally once daily starting Cycle 5 Day 1 when carboplatin is complete or sooner if carboplatin discontinued earlier than Cycle 4. Eligible participants will be given an option to enter LTE phase and DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Lazertinib will be administered as an oral tablet.
Outros nomes:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
|
Experimental: Cohort 3b(Exon19del/Exon21 L858R NSCLC, 2L, Post Osimertinib): Amivantamab (Q3W)+Chemotherapy
Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
|
Experimental: Cohort 4(Previously Treated with Amivantamab IV): Switch from Amivantamab IV to SC-CF (Q2W)
Participants who were previously on amivantamab IV once every 2 weeks (Q2W) regimen as part of standard of care, for at least 8 weeks, either as monotherapy or combination with lazertinib, will receive amivantamab SC-CF injection 1600 mg and 2240 mg if body weight is greater than or equal to 80 kg. Participants who continue to benefit from study treatments, as determined by their investigator, may shift to the drug access (DA)-LTE phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Lazertinib will be administered as an oral tablet.
Outros nomes:
|
|
Experimental: Cohort 5(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q4W) + Lazertinib
Participants with treatment-naïve locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation will receive amivantamab SC-CF induction with 1,600 mg (or 2,240 mg if BW >=80 kg) on Cycle 1 Days 1, 8, 15, and 22, starting with Cycle 2 on Day 1 of each next 28-day cycle, amivantamab SC-CF (160 mg/mL co-formulated with rHuPH20) by manual injection at 3,520 mg (or 4,640 mg if BW >=80 kg); along with lazertinib 240 mg by mouth once daily from Cycle 1 Day 1. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Lazertinib will be administered as an oral tablet.
Outros nomes:
|
|
Experimental: Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Anticoagulant
Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation treated will receive will receive amivantamab SC-CF injection, 1600 milligrams (mg) and 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily from Cycle 1 Day 1. Participants will additionally take prophylactic anticoagulation with a direct oral anticoagulant (DOAC) or a low molecular weight heparin (LMWH) for the first four months of study treatment (from Day 1 through Day 120) with the combination of amivantamab and lazertinib. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Lazertinib will be administered as an oral tablet.
Outros nomes:
DOAC will be administered orally. LMWH will be administered subcutaneously. |
|
Experimental: Cohort 7(Exon19del/Exon21 L858R NSCLC,2L,Post Amivantamab+Lazertinib):Amivantamab(Q3W)+Chemotherapy
Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after the combination of amivantamab and lazertinib will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
Outros nomes:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV)
Prazo: Up to 1 year 6 months
|
ORR based on INV will be reported. ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by investigator. |
Up to 1 year 6 months
|
|
Cohort 4: Number of Participants with Adverse Events (AEs)
Prazo: Up to approximately 4 years and 9 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to approximately 4 years and 9 months
|
|
Cohort 4: Number of Participants with AEs by Severity
Prazo: Up to approximately 4 years and 9 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 4 years and 9 months
|
|
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values
Prazo: Up to approximately 4 years and 9 months
|
Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported. |
Up to approximately 4 years and 9 months
|
|
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity
Prazo: Up to approximately 4 years and 9 months
|
Number of participants with laboratory values abnormalities which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 4 years and 9 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All Cohorts Except Cohort 4: Number of Participants with AEs
Prazo: Up to 1 year 6 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with AEs by Severity
Prazo: Up to 1 year 6 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values
Prazo: Up to 1 year 6 months
|
Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity
Prazo: Up to 1 year 6 months
|
Number of participants with abnormalities in clinical laboratory values which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: ORR Based on Independent Central Review (ICR)
Prazo: Up to 1 year 6 months
|
ORR based on ICR will be reported. The ORR is defined as the percentage of participants who achieve a CR or PR, based on RECIST version 1.1, as confirmed by ICR. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Duration of Response (DoR) Based on Investigator Assessment (INV)
Prazo: Up to 1 year 6 months
|
DoR based on INV is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Time to Response (TTR) Based on INV
Prazo: Up to 1 year 6 months
|
TTR (that is, time to first response) based on INV is defined as the time from the first dose of study treatment to the date of first documentation of a response (PR or CR) prior to any disease progression and subsequent anticancer therapy, based on RECIST version 1.1., for participants who have PR or CR as their best response. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Clinical Benefit Rate (CBR)
Prazo: Up to 1 year 6 months
|
CBR is defined as the percentage of participants achieving CR or PR, or durable standard deviation (SD) of a duration of at least 11 weeks as defined by RECIST version 1.1. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Progression-free Survival (PFS)
Prazo: Up to 3 years
|
The PFS is defined as the time from the first dose of study treatment until the date of objective disease progression or death, whichever comes first, based on RECIST version 1.1. |
Up to 3 years
|
|
All Cohorts Except Cohort 4: Overall Survival (OS)
Prazo: Up to approximately 4 years
|
The OS is defined as the time from the first dose of study treatment until the date of death due to any cause. |
Up to approximately 4 years
|
|
All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE)
Prazo: Up to 1 year 6 months
|
Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE) by Severity
Prazo: Up to 1 year 6 months
|
Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) by severity will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) of Amivantamab
Prazo: Cycle 2 Day 1 of 28-day cycle
|
Ctrough is defined as the serum concentration of amivantamab immediately prior to the next drug administration. |
Cycle 2 Day 1 of 28-day cycle
|
|
Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Intravenous (TASQ-IV)
Prazo: Up to 1 year 6 months
|
Patient-reported outcome (PRO): Cancer therapy satisfaction will be assessed using the modified TASQ-IV. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best. |
Up to 1 year 6 months
|
|
Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC)
Prazo: Up to 1 year 6 months
|
PRO: Cancer therapy satisfaction will be assessed using the modified TASQ-SC. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best. |
Up to 1 year 6 months
|
|
Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Change (PGIC) Scale Score
Prazo: Up to 1 year 6 months
|
Patient-reported status as assessed by PGIC scale score will be reported. The PGIC is an assessment of the participant's overall sense of whether there has been a change since starting treatment. The PGIC is a 7-point response scale. Participants will be asked to rate their current fatigue as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse. |
Up to 1 year 6 months
|
|
Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score
Prazo: Up to 1 year 6 months
|
Patient-reported status as assessed by PGIS scale score will be reported. The PGIS is an assessment of lung cancer severity at a given point in time. The PGIS is a 5-point response scale. Participants will be asked to rate their fatigue over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe. |
Up to 1 year 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Respiratórias
- Doenças pulmonares
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias Pulmonares
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Carcinoma pulmonar de células não pequenas
- Aminoácidos, peptídeos e proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Carboidratos
- Complexos de coordenação
- Guanina
- Hipoxantinas
- Purinonas
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Heparina
- Glicosaminoglicanos
- Polissacarídeos
- Pemetrexede
- Carboplatina
- Heparina de Baixo Peso Molecular
- N (4) -eilcitosina Arabinoside
- Amivantamab
- Lazertinibe
Outros números de identificação do estudo
- CR109264
- 2022-000526-21 (Número EudraCT)
- 61186372NSC2002 (Outro identificador: Janssen Research & Development, LLC)
- 2023-505065-91-00 (Identificador de registro: EUCT number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .